The Judicial Panel for Multidistrict Litigation has approved a request to centralize dozens of cases in the U.S. District Court for the District of New Jersey over allegations that the diabetes drug Invokana caused kidney failure and ketoacidosis, a serious condition in which too much acid builds up in the blood.
There are currently 29 cases filed in the New Jersey federal court. The order brings the total to 55. The panel expects an additional 44 to be transferred from districts in Minnesota, Illinois, Kentucky, Missouri, Virginia and West Virginia.
The lawsuits allege Invokana makers Johnson & Johnson subsidiary Janssen Pharmaceuticals and Mitsubishi Tanabe Pharmaceuticals failed to adequately warn of Invokana side effects and improperly marketed the drug. They also claim the drug was defectively designed because it prevents the body from metabolizing excess sugar in the blood by directing it through the kidneys where it is excreted in the urine.
Invokana, which contains the active ingredient canagliflozin, is the top-selling medication in a class of type 2 diabetes treatments known as SGLT2 inhibitors. Since the drug was approved in 2013, the Food and Drug Administration (FDA) has added new warnings or strengthened existing warnings on SGLT2 inhibitors regarding risks for bone mineral density loss, bone fracture, serious urinary tract infections, acute kidney injury or kidney failure, lower limb amputations, and ketoacidosis.
Attorneys with Beasley Allen Law Firm are currently investigating cases of ketoacidosis, kidney injury, or kidney failure in people who have taken Invokana or Invokamet, a combination of canagliflozin and insulin.
Source: New Jersey Law Journal